NASDAQ:AGIOAgios Pharmaceuticals Stock Price, Forecast & News

Agios Pharmaceuticals' stock was trading at $40.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AGIO stock has increased by 29.1% and is now trading at $52.78. View which stocks have been most impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Agios Pharmaceuticals.

Agios Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Agios Pharmaceuticals.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) announced its earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.67) by $1.08. The biopharmaceutical company had revenue of $87.10 million for the quarter, compared to analyst estimates of $31.12 million. Agios Pharmaceuticals had a negative net margin of 205.20% and a negative return on equity of 63.85%. The company's quarterly revenue was up 188.4% on a year-over-year basis. During the same period in the previous year, the business posted ($1.59) EPS. View Agios Pharmaceuticals' earnings history.

12 analysts have issued 1-year price targets for Agios Pharmaceuticals' shares. Their forecasts range from $49.00 to $82.00. On average, they anticipate Agios Pharmaceuticals' stock price to reach $66.20 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View analysts' price targets for Agios Pharmaceuticals.

News stories about AGIO stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Agios Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutAgios Pharmaceuticals.

Some companies that are related to Agios Pharmaceuticals include Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Alibaba Group (BABA), bluebird bio (BLUE), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), Micron Technology (MU) and NVIDIA (NVDA).

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

Agios Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (11.44%), BlackRock Inc. (6.58%), Capital International Investors (5.79%), State Street Corp (2.77%), First Trust Advisors LP (1.82%) and Invesco Ltd. (1.77%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, Jacqualyn A Fouse, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View institutional ownership trends for Agios Pharmaceuticals.

AGIO stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, First Trust Advisors LP, Invesco Ltd., BNP Paribas Arbitrage SA, Squarepoint Ops LLC, Wellington Management Group LLP, Rafferty Asset Management LLC, and Rhenman & Partners Asset Management AB. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, and Christopher Bowden. View insider buying and selling activity for Agios Pharmaceuticals.

AGIO stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Rock Springs Capital Management LP, Casdin Capital LLC, Nuveen Asset Management LLC, Alliancebernstein L.P., First Manhattan Co., Alyeska Investment Group L.P., and Geode Capital Management LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene, David P Schenkein, and Jacqualyn A Fouse. View insider buying and selling activity for Agios Pharmaceuticals.

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AGIO stock can currently be purchased for approximately $52.78.

Agios Pharmaceuticals has a market capitalization of $3.64 billion and generates $117.91 million in revenue each year. The biopharmaceutical company earns $-411,470,000.00 in net income (profit) each year or ($6.86) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

The official website for Agios Pharmaceuticals is www.agios.com.

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]